Urinary Tract Infection Treatment Market Scope And Analysis

Report Code : TIPRE00005931
Category : Life Sciences

No. of Pages : 150

Buy Now

Urinary Tract Infection Treatment Market Scope and Analysis Report by 2031

Buy Now

Urinary Tract Infection Treatment Market Report Scope

Report Attribute	Details
Market size in 2023	US$ 10.10 Billion
Market Size by 2031	US$ 13.02 Billion
Global CAGR (2023 - 2031)	3.2%
Historical Data	2021-2022
Forecast period	2023-2031
Segments Covered	By Drug Class Penicillin and Combinations Quinolones Cephalosporin Aminoglycoside Antibiotics Sulphonamides Nutritional Supplements By Indication Complicated Urinary Tract Infection and Uncomplicated Urinary Tract Infection By Distribution Channel Hospital Pharmacies Gynaecology and Urology Clinics Retail Pharmacies and Drug Stores Online Drug Stores
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Almirall SA Dr Reddys Laboratories Ltd Allergan GlaxoSmithKline PLC Shionogi Co Ltd Novartis AG Pfizer Merck Co Inc Bristol Myers Squibb Company Regeneron Pharmaceuticals

Urinary Tract Infection Treatment Market News and Recent Developments

The urinary tract infection treatment Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for urinary tract infection treatment and strategies:

Allecra Therapeutics announced U.S. FDA approval for EXBLIFEP for the treatment of complicated urinary tract infections, including pyelonephritis, in patients 18 years and older. The company also received a five-year marketing exclusivity extension from the FDA as part of the Generating Antibiotic Incentives Now Act (GAIN Act). The GAIN Act, enacted by the U.S. Congress, incentivizes the creation of new anti-infective therapeutics by providing benefits to manufacturers of Qualified Infectious Disease Products (QIDPs). (Source: Allecra Therapeutics GmbH, Newsletter, 2024).
NRx Pharmaceuticals announced that FDA accepts Investigational New Drug (IND) application for its NRX-101 for complicated UTIs. The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs. (Source: NRx Pharmaceuticals, Company Website, 2023).

Urinary Tract Infection Treatment Market Report Coverage and Deliverables

The “Urinary Tract Infection Treatment Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
Market dynamics such as drivers, restraints, and key opportunities
Key future trends
Detailed PEST/Porter’s Five Forces and SWOT analysis
Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
Detailed company profiles